Loading stocks --
Market News
English اردو

Citi Pharma 1QFY27 Net Profit Up 22% YoY to PKR 248.8 Million

CPHL Citi Pharma Ltd.
Rs. 62.18 -0.27%
Stock ImpactPositive

Citi Pharma Limited (PSX: CPHL) recorded a 22.14% year-on-year increase in consolidated net profit for the first quarter ended September 30, 2026 (1QFY27), reaching PKR 248.79 million compared to PKR 203.69 million in the same period last year.

Basic and diluted earnings per share (EPS) grew 22.47% to PKR 1.09 from PKR 0.89. Profitability was supported by a 29.92% surge in gross profit alongside a 16.93% reduction in finance costs, though a sharp rise in marketing expenses (+122.58%) and higher tax charges (+46.47%) partially trimmed the bottom-line expansion.

Financial Metric1QFY27 (PKR)1QFY26 (PKR)YoY Change (%)
Net Sales3,514,442,8883,370,247,6714.28%
Gross Profit674,262,488518,973,62229.92%
Operating Profit511,162,226420,355,03721.60%
Finance Costs(100,672,701)(121,191,504)-16.93%
Profit After Tax248,792,484203,690,87322.14%
EPS (PKR)1.090.8922.47%

Investor Takeaway: Citi Pharma delivered strong bottom-line growth driven by gross margin expansion and reduced financial charges, despite notable selling and tax expense pressures during the quarter.

Read the full story on the original publisher’s website.

Open original article